SCHEDULE 13G/A: Long Focus Capital Entities Disclose 5.0% Stake in Aura Biosciences, Inc.

Long Focus Capital Management, LLC and affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 5.0% in Aura Biosciences, Inc. as of December 24, 2024.

Summary

• The filing is an Amendment No. 1 to Schedule 13G for Aura Biosciences, Inc. (CUSIP: 05153U107).
• The reporting persons include Long Focus Capital Management, LLC, Long Focus Capital Master, LTD., Condagua, LLC, John Helmers, and Glenn Helmers.
• As of December 24, 2024, Long Focus Capital Management, LLC and John Helmers each beneficially own 2,507,774 shares of Common Stock, representing 5.0% of the class.
• Long Focus Capital Master, LTD. beneficially owns 1,782,997 shares, representing 3.6% of the class.
• Condagua, LLC and Glenn Helmers each beneficially own 724,777 shares, representing 1.4% of the class.
• Long Focus Capital Management, LLC, a Delaware entity, acts as the investment adviser for Long Focus Capital Master, LTD., a Cayman Islands entity.
• John Helmers, a U.S. citizen, controls Long Focus Capital Management, LLC and has investment and voting power over Condagua, LLC.
• Glenn Helmers, a U.S. citizen, controls Condagua, LLC, a Delaware entity.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aura Biosciences, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional stake in Aura Biosciences, which can be viewed as a positive signal of investor confidence, although it is a routine disclosure of beneficial ownership and does not contain new financial or operational information.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Aura Biosciences, a biotechnology company. Such investments can signal confidence from professional investors in the company's long-term prospects within the competitive biotech sector, although this specific filing is a routine disclosure of ownership rather than a strategic announcement.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership.
• Investors: Provides insight into institutional interest in Aura Biosciences, potentially signaling confidence in the company's long-term prospects.

Key Dates

Recommendation

Keywords

Aura Biosciences, Long Focus Capital Management, Schedule 13G/A, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals